Recurrence

BostonGene Announces Publication in Nature

Retrieved on: 
Friday, February 16, 2024

BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.
  • Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or “lymphocyte-depleted” tumor microenvironment (TME).
  • "BostonGene's innovative RNA-seq analytics lent novel insights into the dynamic changes associated with CAN-3110 therapy within the glioblastoma microenvironment," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • “Looking to the future, we are excited at the possibilities of harnessing oncolytic viruses to transform immunosuppressive microenvironments across a range of solid cancer types.”

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Retrieved on: 
Thursday, February 15, 2024

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis.
  • MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
Thursday, February 15, 2024

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Retrieved on: 
Wednesday, February 14, 2024

(NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.

Key Points: 
  • (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.
  • Cellular therapies, particularly chimeric antigen receptor T cell therapies (CAR-T), have shown promise in hematologic malignancies but have faced significant challenges when applied to solid tumors like GBM.
  • The INB-200 and INB-400 studies by IN8bio addresses the challenges towards targeting solid tumors by harnessing the innate immune functions of gamma-delta T cells.
  • IN8bio is also conducting a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed GBM.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Tuesday, February 13, 2024

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”

New Research Shows Minimally Invasive Therapy (Middle Meningeal Artery Embolization) is Effective in Treating Chronic Subdural Hematoma

Retrieved on: 
Monday, February 12, 2024

FAIRFAX, Va., Feb. 12, 2024 /PRNewswire/ -- The Society of Neurolnterventional Surgery (SNIS) is acknowledging middle meningeal artery embolization (MMAE) as a beneficial adjunctive treatment for chronic subdural hematoma in light of new research. The minimally invasive MMAE procedure significantly reduced the failure rates of traditional surgical and non-surgical management strategies without an increased rate of serious neurological complications.

Key Points: 
  • Chronic subdural hematoma refers to the gradual accumulation of blood over the surface of the brain.
  • As the U.S. population continues to age, studies show that chronic subdural hematomas may be the most prevalent neurosurgical diagnosis that requires treatment within the next decade.
  • However, an average of 10% to 30% of patients experience recurrence of chronic subdural hematoma after surgery, often necessitating reoperation.
  • Chronic subdural hematoma is an exceedingly common problem, and these findings will be relevant to a large population of patients.

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

Retrieved on: 
Monday, February 12, 2024

Data Summaries from Key Studies:

Key Points: 
  • Data Summaries from Key Studies:
    Subgroup Analyses from the TIMELESS Trial, by Gregory Albers, M.D., presented and simultaneously published in the NEJM.
  • Key imaging criteria: target mismatch ratio of ≥1.8, mismatch volume of ≥15 mL, and ischemic core volume
  • Data showed a median reduction of 30 minutes per patient from door-to-mechanical thrombectomy (MT) after the integration of RapidAI.
  • “In the world of AI, clinical validation is paramount to instill confidence in clinician decision-making,” said Karim Karti, CEO of RapidAI.

Early polls can offer some insight into candidates’ weak points – but are extremely imprecise

Retrieved on: 
Monday, February 12, 2024

Preelection polls have been inescapable early in the 2024 election year, setting storylines, as they invariably do, for journalists and pundits about the race for the presidency.

Key Points: 
  • Preelection polls have been inescapable early in the 2024 election year, setting storylines, as they invariably do, for journalists and pundits about the race for the presidency.
  • At the same time, the polls have delivered reminders that they can be less than precise indicators of outcomes — as was evident in January’s Republican caucus in Iowa and primary in New Hampshire.
  • Although Trump won both states handily, the outcomes signaled anew that polls, however ubiquitous, are best treated warily.

Contradictory polls

  • The early-in-2024 polls assessing a presumptive rematch between Trump and President Joe Biden have broadly signaled a close race, while on occasion presenting whiplash-inducing, contradictory indications.
  • Whiplash results can stem from differences in how pollsters conduct their surveys and how they analyze and statistically adjust their findings.
  • His popular-vote margin in 2020 was 4.5 points, in what overall was the worst performance by polls since 1980.

Why pay any attention to polls?

  • The gap in the recent CNN and Quinnipiac poll results gives rise to an important question: Why, at such an early moment in the campaign, should voters pay any attention to preelection surveys?
  • When considered collectively, however, polls can offer intriguing insights about a developing race, some of which are apparent only in hindsight.
  • On Feb. 29, 2012, Barack Obama led Republican contender Mitt Romney by 4 percentage points in the RealClearPolitics polling average.
  • So it’s prudent not to over-interpret survey results reported early in the campaign, however accurate they may prove to be.

Will the polls get it right in 2024?

  • Outcomes in those and other swing states in November could determine who wins the presidency — much as they did in 2020.
  • It’s certainly “a live issue” whether the polls will get it right in 2024, as an academic journal article noted not long ago.
  • As I write in “Lost in a Gallup,” discrepancies between polling results and presidential election outcomes can have unsettling effects.


W. Joseph Campbell does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Piero Cipollone: Modernising finance: the role of central bank money

Retrieved on: 
Saturday, February 10, 2024

The paper demonstrates how agreement-level data can be used to study drivers of aggregate negotiated wage growth, as well as monitor the breadth of wage increases and account for time-varying factors such as one-off payments, when assessing wage pressures.

Key Points: 
  • The paper demonstrates how agreement-level data can be used to study drivers of aggregate negotiated wage growth, as well as monitor the breadth of wage increases and account for time-varying factors such as one-off payments, when assessing wage pressures.
  • Lastly, the paper shows that the new indicators can provide reliable signals about current and future developments of wage pressures in the euro area while also serving as important cross-checking tools for negotiated wage growth forecasts.